Jing Ji Guan Cha Wang·2025-11-07 06:55Core Viewpoint - Fosun Pharma has launched an innovative treatment solution for Parkinson's disease during the 8th China International Import Expo, addressing global challenges in managing motor symptoms for mid-to-late stage patients [1] Group 1: Treatment Solution - The solution combines the drug Opicapone with a "magnetic knife" technology to manage early symptoms and treat tremors in advanced stages, reducing drug dependency and side effects [1] - Opicapone is a third-generation COMT inhibitor that enhances the bioavailability of Levodopa, prolonging its therapeutic effects for Parkinson's patients [1] - The "magnetic knife" utilizes high-intensity focused ultrasound and MRI for precise targeting, offering a non-invasive treatment option without the need for general anesthesia [1] Group 2: Competitive Advantage - This collaborative treatment approach not only improves efficacy but also lowers overall treatment costs, representing a unique competitive advantage for Fosun Pharma in the healthcare market [1] - The launch signifies Fosun Pharma's exploration of new treatment models in the disease management sector [1]